CANY
VIR icon

Caxton Associates (New York)’s Vir Biotechnology VIR Stock Holding History

Caxton Associates (New York)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$524K Hold
71,348
– – 0.02% 321
2024
Q3 		$534K Buy
71,348
+11,723
+20% +$102K 0.02% 353
2024
Q2 		$531K Buy
+59,625
New +$572K 0.02% 331

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Caxton Associates (New York)'s VIR Position: Q4 2024 in Review

Caxton Associates (New York) held its Vir Biotechnology (VIR) position steady in Q4 2024 at 71,348 shares worth $524K. The position accounts for 0.02% of the portfolio, ranked #321.

Caxton Associates (New York) first reported a position in VIR in Q2 2024 and has held it in 3 quarters since. The position peaked at $534K in Q3 2024. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Caxton Associates (New York) held 71,348 shares of Vir Biotechnology worth $524K as of Q4 2024.
  • Caxton Associates (New York) left its Vir Biotechnology share count unchanged in Q4 2024.
  • Vir Biotechnology made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #321 holding.
  • Caxton Associates (New York) first reported a position in Vir Biotechnology in Q2 2024 and has held it in 3 quarters since.
  • Caxton Associates (New York)'s Vir Biotechnology position peaked at $534K in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.